Palisade Bio entered into a master services agreement with Iterative Health to accelerate patient enrollment for the upcoming Phase 2 study of PALI-2108 for Ulcerative Colitis. The company completed a private placement of 1,536,885 shares of common stock to an affiliate of Iterative Health. The total gross proceeds from the stock issuance amounted to $3.0 million. The shares were priced at $1.952 per share, based on the five-day average closing price on the Nasdaq prior to the March 27, 2026 closing date.